>>Biotech rule of thumb: If it's a piece of information that bodes well for the trial, then 90% of small biotechs will make sure it is stated clearly and advantageously in the PR.
Conversely, if there are ambiguities, they are there because the specifics themselves may add a negative hue to the results.<<